The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Guidepoint Qsight, a leader in leveraging proprietary data to provide unmatched analytics solutions, today revealed new ...

Dolores was one of the first Real Housewives stars to open up about using weight-loss drugs. In 2023, she told The Sun that ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

British fund manager Terry Smith has sold his stake in Diageo Plc, citing concerns about the management of the drinks company ...

Britain's Terry Smith made public for the first time on Thursday why his fund dumped its Diageo stake last year, citing ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

It is a fair bet to guess that many people taking drugs such as Ozempic are just tired of being fat. The hitch with Ozempic, however, is that is precisely its common purpose.